What was the overall financial performance of Stryker in the reported period?

Stryker demonstrated robust financial performance, with significant year-over-year increases in net sales and net earnings from continuing operations for both the nine-month and third-quarter periods ending September 30, 2007. Diluted earnings per share also saw substantial growth.

How did the divestiture of Physiotherapy Associates impact the company?

The sale of Physiotherapy Associates in the second quarter of 2007 was a strategic move to focus on the medical technology market. It resulted in a gain of $25.7 million for the company and removed the associated operating results from discontinued operations.

What is the company's outlook for the remainder of 2007?

Stryker's outlook is optimistic. The company projects diluted net earnings per share from continuing operations to be around $2.37 for the full year 2007, representing a 27% increase compared to 2006. They also anticipate continued sales growth in the range of 13.0% to 13.5% on a constant currency basis.

Are there any significant ongoing legal or regulatory matters affecting Stryker?

Yes, Stryker is cooperating with investigations by the U.S. Department of Justice regarding consulting contracts with orthopedic surgeons and antitrust matters related to orthopaedic implant devices. Additionally, the SEC is making an informal inquiry concerning possible violations of the Foreign Corrupt Practices Act in certain foreign countries. The company has resolved an investigation related to its Orthopaedics subsidiary via a non-prosecution agreement.

SYK 10-Q Quarterly Report Q3 FY2007 — Revenue, Net Income, EPS

Summary

Stryker Corporation reported strong financial performance for the nine months and third quarter ending September 30, 2007. Net sales showed significant year-over-year growth, driven by both domestic and international markets, with notable strength in the Orthopaedic Implants and MedSurg Equipment segments. The company also demonstrated improved profitability, with net earnings and diluted EPS from continuing operations increasing substantially compared to the prior year periods. This growth was supported by increased unit volume and favorable product mix, alongside effective management of cost of sales and operating expenses. The company successfully divested its outpatient physical therapy business, Physiotherapy Associates, which resulted in a gain on sale. Management's outlook for the full year 2007 remains optimistic, projecting a significant increase in diluted net earnings per share. Stryker is also actively investing in research and development to fuel future product launches, indicating a strategic focus on innovation and market expansion.

Key Highlights

1Net sales for the nine months ended September 30, 2007, increased 16% to $4,342.4 million, with an 18% increase for the third quarter to $1,453.2 million.
2Net earnings from continuing operations for the nine months increased 30% to $710.6 million, with diluted EPS rising to $1.70.
3Third quarter net earnings from continuing operations increased 22% to $228.7 million, with diluted EPS at $0.55.
4The Orthopaedic Implants segment showed a 14% sales increase for the nine months, while the MedSurg Equipment segment grew by 19%.
5The company completed the sale of its outpatient physical therapy business (Physiotherapy Associates) in the second quarter of 2007, resulting in a gain of $25.7 million.
6Stryker's outlook for 2007 projects diluted net earnings per share from continuing operations to approximate $2.37, an increase of 27% over 2006.
7The company continues to invest in R&D, with expenses increasing 17% for the nine months and 20% for the third quarter, reflecting a commitment to new product development.

STRYKER CORP Quarterly Report for Q3 Ended Sep 30, 2007

Summary

Key Highlights

Frequently Asked Questions